Ionis Pharmaceuticals Inc
IONS42.480USD
-0.950-2.19%
종가 08/19, 16:00（ET）시세는 15분 지연됩니다
6.76B시가총액
손실P/E TTM
자세한 내용은 Ionis Pharmaceuticals Inc 회사
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
회사 정보
종목 코드 IONS
회사 이름Ionis Pharmaceuticals Inc
상장일May 17, 1991
CEODr. Brett P. Monia, Ph.D.
직원 수1069
유형Ordinary Share
회계 연도 종료May 17
주소2855 Gazelle Court
도시CARLSBAD
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호92010
전화17609319200
웹사이트https://www.ionis.com/
종목 코드 IONS
상장일May 17, 1991
CEODr. Brett P. Monia, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.82K
-0.64%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
89.49K
-10.05%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
-16.75%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
+12.65%
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.82K
-0.64%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
89.49K
-10.05%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
수익 분석
통화: USD마지막 업데이트: Tue, Mar 4
통화: USD마지막 업데이트: Tue, Mar 4
FY2020
FY2019
사업별USD
이름
수익
비율
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
데이터 없음
사업별
지역별
사업별USD
이름
수익
비율
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
주식 보유 통계
마지막 업데이트: Sat, Aug 16
마지막 업데이트: Sat, Aug 16
주주
주주 유형
주주
주주
비율
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
기타
51.29%
주주
주주
비율
Fidelity Management & Research Company LLC
14.83%
The Vanguard Group, Inc.
10.47%
T. Rowe Price Investment Management, Inc.
10.07%
Capital World Investors
7.87%
BlackRock Institutional Trust Company, N.A.
5.47%
기타
51.29%
주주 유형
주주
비율
Investment Advisor
71.14%
Hedge Fund
16.49%
Investment Advisor/Hedge Fund
16.46%
Research Firm
2.04%
Private Equity
1.59%
Pension Fund
1.12%
Individual Investor
0.81%
Bank and Trust
0.66%
Sovereign Wealth Fund
0.28%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Two Sigma Investments, LP
3.78M
2.37%
+1.51M
+66.38%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Wed, Aug 6
마지막 업데이트: Wed, Aug 6
이름
비율
Tema Neuroscience and Mental Health ETF
3.69%
ARK Genomic Revolution ETF
3.41%
Virtus LifeSci Biotech Products ETF
2.32%
SPDR S&P Biotech ETF
1.56%
WisdomTree BioRevolution Fund
1.35%
Tema Heart & Health ETF
1.08%
Direxion Daily S&P Biotech Bull 3X Shares
1.01%
Capital Group US Small and Mid Cap ETF
0.92%
iShares Health Innovation Active ETF
0.88%
Franklin Genomic Advancements ETF
0.83%
더 보기
Tema Neuroscience and Mental Health ETF
비율3.69%
ARK Genomic Revolution ETF
비율3.41%
Virtus LifeSci Biotech Products ETF
비율2.32%
SPDR S&P Biotech ETF
비율1.56%
WisdomTree BioRevolution Fund
비율1.35%
Tema Heart & Health ETF
비율1.08%
Direxion Daily S&P Biotech Bull 3X Shares
비율1.01%
Capital Group US Small and Mid Cap ETF
비율0.92%
iShares Health Innovation Active ETF
비율0.88%
Franklin Genomic Advancements ETF
비율0.83%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
